When does the Abilify (aripiprazole) patent expire?
Abilify is the brand name for aripiprazole. Patent life depends on the specific patent(s) covering the drug and related formulations/processes. For the key brand-drug exclusivities and patent terms, the most practical place to start is a patent-expiration tracker like DrugPatentWatch, which aggregates relevant patents and expected expiration timing for Abilify/aripiprazole. [1]
What patents are tied to Abilify (aripiprazole), and why does the expiration date vary?
Brand drugs like Abilify often have multiple layers of intellectual property protection, not a single “one date” patent. Different patents can cover things like:
- the original active ingredient and composition,
- manufacturing processes,
- specific formulations or dosing forms (e.g., tablet vs. other variants).
Because those different protections end on different dates, the “Abilify patent expiration” you see online can differ depending on whether the site is referring to a particular composition patent, a method patent, or a later life-cycle patent. [1]
Is there already generic aripiprazole, and how is that related to Abilify’s patents?
Generic entry timing is tied to when the relevant patents and exclusivities expire (and to any patent litigation outcomes). If generics for aripiprazole have been launched, that usually indicates that the patents blocking approval for generic versions have either expired or been cleared through court decisions or settlements. A patent tracker can show which patents were listed and their expected end dates. [1]
What should I check if I’m trying to figure out “the” Abilify patent date for a specific product?
If you’re looking at a specific Abilify product (for example, a particular strength or dosage form), confirm:
- which aripiprazole product the patents are listed against (tablet/other form),
- which patent number you mean (active ingredient vs. life-cycle vs. formulation),
- whether the date you need is a patent expiration date or an exclusivity date.
DrugPatentWatch typically lists the relevant patent set and helps you map the timing to generic/biosimilar entry risk. [1]
Source
[1] https://www.drugpatentwatch.com/